Is this when they "COOKED" up the Pandemic? Mixed all the other manufactured virus' into one super virus? Along with the CCP? Had to pretend to "shut down" gain of fuction here, only to continue there?
Just a few short months later he made this…
Executive Order – Revised List of Quarantinable Communicable Diseases
July 31, 2014
https://obamawhitehouse.archives.gov/the-press-office/2014/07/31/executive-order-revised-list-quarantinable-communicable-diseases
HIV has a SPIKE complex, just like Covid.
If [THEY] took parts of the HIV, ZIKA, SARS, CoV, etc, it would make sense.
The spike protein on the virus surface mediates its entry to the host cell and a high spike density promotes infection. HIV has a spike density that is almost two orders of magnitude lower than other viruses. This unique feature of HIV has defied explanation since it was first observed.
https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1006408#:~:text=The%20spike%20protein%20on%20the,since%20it%20was%20first%20observed.
The SARS-CoV-2 spike glycoprotein is a focal point for vaccine immunogen and therapeutic antibody design, and also serves as a critical antigen in the evaluation of immune responses to COVID-19. A common feature amongst enveloped viruses such as SARS-CoV-2 and HIV-1 is the propensity for displaying host-derived glycans on entry spike proteins. Similarly displayed glycosylation motifs can serve as the basis for glyco-epitope mediated cross-reactivity by antibodies, which can have important implications on virus neutralization, antibody-dependent enhancement (ADE) of infection, and the interpretation of antibody titers in serological assays. From a panel of nine anti-HIV-1 gp120 reactive antibodies, we selected two (PGT126 and PGT128) that displayed high levels of cross-reactivity with the SARS-CoV-2 spike. We report that these antibodies are incapable of neutralizing pseudoviruses expressing SARS-CoV-2 spike proteins and are unlikely to mediate ADE via FcγRII receptor engagement. Nevertheless, ELISA and other immunoreactivity experiments demonstrate these antibodies are capable of binding the SARS-CoV-2 spike in a glycan-dependent manner. These results contribute to the growing literature surrounding SARS-CoV-2 S cross-reactivity, as we demonstrate the ability for cross-reactive antibodies to interfere in immunoassays.
https://www.biorxiv.org/content/10.1101/2021.01.03.425141v1.full